Rituximab 100 & 500 Cipla 100 & 500 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 01 April 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various B-cell malignancies and autoimmune diseases.
Dosage (summary)
375 mg/mu00b2 IV weekly for 4 doses for NHL; 1000 mg IV for RA, 2 doses 2 weeks apart.
Special Populations
- Elderly
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Fludarabine
- Cyclophosphamide
- Methotrexate
Contraindications
- Hypersensitivity to rituximab
- Active severe infections
- Severe heart failure
Common side effects
- Infusion-related reactions
- Infections
- Neutropenia
Counselling Points
- Monitor for infusion reactions
- Avoid live vaccines
- Screen for HBV before treatment
Serious warnings
- Infusion-related deaths
- Tumour Lysis Syndrome
- Progressive multifocal leukoencephalopathy
Important Disclaimer
The Rituximab 100 & 500 Cipla 100 & 500 mg Concentrate for solution for infusion professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
